Novo Nordisk Argentina Novo Nordisk’s largest insulin production facility outside of Denmark is in Latin America, in Brazil. Can you explain the strategic importance of this for Argentina, and how Novo Nordisk is structured here in the country? Here in Argentina Novo Nordisk has an affiliate focused on commercial activities, clinical research and…
Bayer Schering Pharma Argentina The Bayer Schering merger in 2006 saw you add Argentina and Bolivia to your existing responsibilities as General Manager of Schering for Paraguay and Uruguay. What have been some of the challenges you have faced since that time? Argentina is a challenging market, and the system is very complex. This…
IMS Health Argentina It’s safe to assume that everywhere that IMS Health is established, there’s also a flourishing pharmaceutical industry. Could you give us an overview of Argentina’s IMS operations? IMS has been in Argentina for 35 years, working in information services. Two years ago, we started to offer our customers consulting services.…
Genetic Immunity Genetic Immunity has been founded in 1998. What drove you to set up the company at that time? J.L: To understand the context better, I first need to give a little bit of background on myself. I left for Germany right after I finished university in Hungary, where I was…
Amgen Russia Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been the specific effects of these and other initiatives on the biopharmaceutical sector and the biopharmaceutical market? If you look at…
Biocon If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage in an infrastructure deficient Bangalore. Both India and Biocon have come a long way since then. How different is the…
Celgene Russia Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and internal reasons, which coincided in this case. The external reason was the launch of the reimbursement system in Russia, which…
Amgen B.V. You are still relatively new to the Netherlands having been here for one year. This must be a very insightful experience abroad. What were your initial expectations and first impressions when first starting here and how have they evolved over the course of your year as head of Amgen in…
British Generic Manufacturers Association (BGMA) Together with Germany, the UK the highest generic penetration rate in Europe. Since you have been with the association since 1995 and obviously saw the great emergence of the generic medicines, can you please explain the success of generic medicines in the UK? The important aspect about the UK, which…
Philippines In an exclusive interview, Benjamin Liuson, president of The Generics Pharmacy in the Philippines on the company’s illustrious history, remarkable growth, and increasing acceptance of generics more generally in the Philippines. The Generics Pharmacy originated from a family business and you are the visionary who transformed it into what it…
Celgene Taiwan Could you please give our readers an overview of the importance of Taiwan for Celgene in a regional and a global context? What is attractive in Taiwan for Celgene? Celgene is very new entrant in the multinational context as a latecomer to the market. As a biopharmaceutical company it is…
France Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in biosimilars, becoming a pioneer in a fast-growing niche. How have these two steps helped reshape Sandoz internally? With the creation…
See our Cookie Privacy Policy Here
